-
-
-
-
-
-
-
Artiva Biotherapeutics to present AlloNK data at February medical meeting
-
-
-
-
-
-
-
Artiva Biotherapeutics (ARTV) Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab
-
-
-
-
-
-
-
Artiva Biotherapeutics (ARTV) Appoints Alison Moore to its Board
-
-
-
-
-
-
-
Artiva Biotherapeutics (ARTV) Prices 13.92M Share IPO at $12/sh
-
417,043 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

